Novo's diabetes drug Ozempic and Wegovy are from the class called GLP-1 receptor agonists, and both contain the active ingredient semaglutide, originally developed to help control blood sugar in patients with diabetes. Ozempic is approved for treatment of type 2 diabetes, while Wegovy is approved for weight loss.
from Top Health News | Latest Healthcare Sector & Healthcare Industry news, Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/gWjr8mB
Home »
Information and Updates: ET HealthWorld : ETHealthworld.com
,
Top Health News | Latest Healthcare Sector & Healthcare Industry news
» Novo Nordisk: obesity drugs priority over century-old focus on insulin
https://ift.tt/LdKqmyx
No comments:
Post a Comment